Total number of voting rights and share capital in Novo Nordisk A/S
as of 29 June 2007
In accordance with Section 6 of the Danish Statutory Order on Issuers
Disclosure Obligations, Novo Nordisk is required to publish the total
number of voting rights and the size of the share capital in Novo
Nordisk as per the end of the month where changes have occurred.
Referring to Stock Exchange Announcement no 16/2007 dated 19 June
2007, please find below a statement regarding the total number of
voting rights and share capital in Novo Nordisk as per 29 June 2007.
+-------------------------------------------------------------------+
| | Number of shares | Nominal value | Number of votes |
| | (nominal value | (DKK) | |
| | DKK 2) | | |
|----------+----------------------+---------------+-----------------|
| | | | |
| A shares | | 107,487,200 | 1,074,872,000 |
| | 53,743,600 | | |
|----------+----------------------+---------------+-----------------|
| | | | |
| B shares | | 539,472,800 | |
| | 269,736,400 | | 539,472,800 |
+-------------------------------------------------------------------+
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in the
industry, including the most advanced products within the area of
insulin delivery systems. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone
therapy and hormone replacement therapy. Novo Nordisk manufactures
and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. With headquarters in Denmark, Novo Nordisk employs more than
23,600 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges
in Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 18 / 2007